

REVIEW ARTICLE

The Contribution of Dr. Jonas Salk to the Field of Paediatrics

Kasumbiwal Ajay H.¹, Lakhe Siddheshwar A.², Mundhe Sudarshan R.³, Ritika⁴

How to cite this article:

Kasumbiwal Ajay H., Lakhe Siddheshwar A., Mundhe Sudarshan R., et al. The Contribution of Dr. Jonas Salk to the Field of Paediatrics. *Pediatr. Edu. Res.* 2025; 13(2): 518-520.

ABSTRACT

Dr. Jonas Edward Salk, an American physician and pioneering virologist, made one of the most transformative contributions to pediatric medicine through the development of the first safe and effective inactivated polio vaccine (IPV). At a time when poliomyelitis caused widespread childhood paralysis and mortality, Salk's commitment to creating a killed-virus vaccine led to a scientific breakthrough that dramatically changed global public health. His landmark 1954 field trial one of the largest in medical history demonstrated the vaccine's safety and efficacy, leading to rapid worldwide adoption. The introduction of IPV resulted in an unprecedented decline in polio incidence, protecting millions of children from paralysis and disability. Beyond this achievement, Salk founded the Salk Institute for Biological Studies, which continues to advance research in virology, immunology, and neuroscience. His work overcame scientific skepticism, technical challenges, and public fear, ultimately transforming polio from a dreaded pediatric disease to one nearing global eradication. Salk's humanitarian legacy, including his refusal to patent the vaccine, remains a cornerstone of modern medical ethics and pediatric healthcare.

KEYWORDS

- Jonas Salk • Inactivated Polio Vaccine (IPV) • Poliomyelitis • Pediatric medicine
- Public health • Vaccine development • Polio eradication • Salk Institute

AUTHOR'S AFFILIATION:

¹ Professor & HOD, Department of Pediatrics, VDGM, Latur, Maharashtra, India.

² Assistant Professor, Department of Pediatrics, VDGM, Latur, Maharashtra, India.

³ Senior Resident, Department of Pediatrics, VDGM, Latur, Maharashtra, India.

⁴ Student, Department of Pediatrics, VDGM, Latur, Maharashtra, India.

CORRESPONDING AUTHOR:

Ritika, Student, Department of Pediatrics, VDGM, Latur, Maharashtra, India.

E-mail: yritika0304@gmail.com

➤ Received: 11-12-2025 ➤ Accepted: 25-12-2025



Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC): This article is distributed under the terms of the Creative Commons Attribution NonCommercial 4.0 License (<http://www.creativecommons.org/licenses/by-nc/4.0/>) which permits non-Commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the Red Flower Publication and Open Access pages (<https://www.rfppl.co.in>)

INTRODUCTION

Dr. Jonas Edward Salk (1914–1995) was an American physician, virologist, and medical researcher best known for developing the first safe and effective inactivated polio vaccine. His discovery marked one of the greatest breakthroughs in pediatric medicine, dramatically reducing childhood paralysis and death caused by poliomyelitis a major global health threat in the mid-20th century.

Background:

Born in New York City in 1914, Salk studied medicine at New York University.

Initially interested in internal medicine, he later shifted to virology, training under Dr. Thomas Francis Jr., a leading influenza researcher. In the 1940s–1950s, polio was a devastating pediatric disease, especially in the United States, paralyzing or killing thousands of children each summer. Parents lived in fear, and hospitals were filled with young patients in wheelchairs or “iron lungs” (respirators). Salk’s mission became clear: to create a vaccine that could protect children from polio.

Scientific Contributions

1. **Development of the Inactivated Polio Vaccine (IPV):** In 1952, Salk and his team developed a vaccine using killed poliovirus that was safe and effective. In 1954, the vaccine underwent the largest clinical trial in history at that time, involving more than 1.8 million children, known as the “Polio Pioneers.” In April 1955, the vaccine was declared safe and effective.
2. **Impact on Pediatrics:** The introduction of IPV drastically reduced polio cases worldwide. In the U.S., polio cases dropped from more than 35,000 annually in the early 1950s to fewer than 100 cases by the 1960s. Millions of children were protected from paralysis, disability, and death.
3. **Salk Institute for Biological Studies:** Founded in 1963 in La Jolla, California.

Became a center for pediatric and medical research in virology, genetics, immunology, and neuroscience.

Challenges and Breakthrough

Scientific skepticism: Many researchers believed only a live attenuated virus (later developed

by Albert Sabin) could work. Public fear: Parents were hesitant to let their children be part of trials. Technical hurdles: Ensuring the virus was fully inactivated without destroying its antigenic properties.

Breakthroughs successfully proving that a killed-virus vaccine could provide lasting immunity.

Large-scale immunization campaigns turned polio from a dreaded pediatric disease into one on the brink of eradication.

Reflecton

Dr. Jonas Salk’s work represents not only a scientific achievement but also a humanitarian legacy. He chose not to patent the polio vaccine, famously saying: “Could you patent the sun?” This selfless act ensured global accessibility, saving millions of children worldwide. His contributions highlight the profound impact of medical science on paediatrics, public health, and society at large.

CONCLUSION

Dr. Jonas Salk’s inactivated polio vaccine revolutionized pediatric medicine by preventing paralysis and death in children across the world. His legacy extends beyond polio eradication efforts; he inspired generations of pediatricians, researchers, and public health experts. Today, polio remains close to global eradication, a testament to Salk’s vision, dedication, and humanitarian spirit.

Conflict of Interest

The authors declare that there are no conflicts of interest.

REFERENCES

1. Tan S.Y., Ponstein N. Jonas Salk (1914–1995): A vaccine against polio. Singapore medical journal. 2019 Jan; 60(1): 9.
2. Kleiss K.M. Dr. Jonas Salk. Primary care update for ob/gyns. 2003 May 1; 10(3): 127-8.
3. Sahu H., Choudhari S.G., Gaidhane A., Chakole S. Jonas Salk (1914–1995): Pioneering the fight against polio and beyond. Cureus. 2024 Sep 18; 16(9).
4. Valiunas A. Jonas Salk, the people’s scientist. The New Atlantis. 2018 Jul 1(56): 99-128.
5. Salk J., Salk J. A new reality: Human evolution for a sustainable future. Simon and Schuster; 2018 Jun 26.

6. Beeks J.C. A New Reality: Human Evolution for a Sustainable Future by Jonas Salk and Jonathan Salk: Salk, Jonas, and Jonathan Salk. A New Reality: Human Evolution for a Sustainable Future. Stratford, CT: City Point Press, 2018 (251 pp., \$17.10 USD, ISBN: 978-1-947951-04-4).
7. Aronson S.M. Jonas Salk, Medical Sleuth and Scientist. Rhode Island Medical Journal. 2020 Aug 1; 103(6): 87-.
8. Kluger J. Splendid solution: Jonas Salk and the conquest of polio. Penguin; 2006 Feb 7.
9. Salk J.E., Suriano P.C. Importance of Antigenic Composition of Influenza Virus Vaccine in Protecting against the Natural Disease: Observations during the Winter of 1947-1948. American Journal of Public Health and the Nations Health. 1949 Mar; 39(3): 345-55.